Long-term Survival Data from Longeveron's ELPIS 1 Trial Acce

Long-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

Long-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Miami , Florida , United States , Japan , Philadelphia , Pennsylvania , American , Contactmike Moyerlifesci Advisorstel , Sunjay Kaushal , Exchange Commission , Longeveron Inc , Longeveron Or Company , Nasdaq , Exchange Commission On , Drug Administration , American Heart Association , Scientific Sessions Of The American Heart Association , Aging Related Frailty , Long Term Transplant Free Survival Is Improved , Hypoplastic Left Heart Syndrome , Cell Based Therapy , Scientific Sessions , Rare Pediatric Disease Designation , Fast Track Designation , Orphan Drug Designation , Longeveron Rights , Rights Day , Period Begins , Period Ends , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,